| Meir Stampfer, MD, DrPH, Harvard Medical School |
Dr. Meir Stampfer is a Professor of Medicine at Harvard Medical School and Professor of Epidemiology at Harvard School of Public Health, where he served as department chair. He has authored over 800 articles and book chapters, and was identified as the most highly cited scientist in clinical medicine over the past two decades. He is an active investigator with multiple NIH grants, and his research has focused on cardiovascular disease and cancer.
|
|
| Bert Vogelstein, MD, Johns Hopkins Medical Institutes |
Dr. Bert Vogelstein was the first to elucidate the molecular basis of a common human cancer. His work on colorectal cancers forms the paradigm for much of modern cancer research, with profound implications for diagnostic and therapeutic strategies in the future. According to the Institute for Scientific Information, Dr. Vogelstein is currently the most highly cited scientist in the world. Dr. Vogelstein is Director of the Ludwig Center for Cancer Genetics and Therapeutics, an Investigator of the Howard Hughes Medical Institute, and the Clayton Professor of Oncology and Pathology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Awards recognizing his accomplishments include the Bristol Myers Squibb Award, the American Cancer Society Medal of Honor, the Gairdner Foundation International Award in Science, the Shacknai Memorial Prize, The Dickson Prize, the Louisa Gross Horwitz Prize, The Harvey Prize, the Pezcoller Foundation Award, the Association of American Medical College Baxter Award, the Howard Taylor Ricketts Award, the Ernst Schering Prize, the Passano Award, the American Association for Cancer Research Clowes Memorial Award, the American Gastroenterological Association William Beaumont Prize, the American Society for Clinical Oncology Karnofsky Memorial Award, the Paul Ehrlich and Ludwig Darmstaedter Prize, the American Society of Human Genetics William Allan Award, the National Academy of Sciences Richard Lounsbery Award, the General Motors Cancer Research Foundation Charles S. Mott Prize, the John Scott Award, the Prince of Asturias Award in Science, the New York Academy of Medicine Medal for Distinguished Contributions to Biomedical Science, and the American Research Forum Pioneer in Science Award. Dr. Vogelstein has been elected to the American Academy of Arts & Sciences, the National Academy of Sciences, EMBO, and the American Philosophical Society. He has held editorial positions at journals including Science and The New England Journal of Medicine. His advisory roles have included Chairmanship of the National Research Council Committee on the Biological and Biomedical Applications of Stem Cell Research as well as Chairmanship of the Board of Scientific Counselors of the National Human Genome Research Institute.
|
|
| Michael Kastan, MD, PhD; St. Jude Children's Research Hospital |
Michael Kastan, MD, PhD, a Pediatric Oncologist and active laboratory investigator, is the Director of the Cancer Center at St. Jude Children’s Research Hospital. Dr. Kastan made the seminal discovery that the p53 tumor suppressor protein participates in cellular responses to DNA damage. The manuscripts reporting this discovery are among the most highly cited scientific publications of the 1990’s. Over the past several years, Dr. Kastan's work has continued to elucidate molecular events involved in DNA damage and cellular stress responses with a focus on the ATM-p53 pathway and development of novel approaches to modulate cellular responses to oxidative stress, irradiation and carcinogens. Dr. Kastan previously served on the Board of Directors of the American Association for Cancer Research AACR) and served as Chairman of the Board of Scientific Counselors of the National Cancer Institute (NCI). He is currently Editor-in-Chief of the journal Molecular Cancer Research and Editor of the textbook Clinical Oncology. He has received a MERIT award from the NIH, has been honored by the American Association for Cancer Research with the GHA Clowes Memorial Award for outstanding contributions to basic cancer research, by the Leukemia/Lymphoma Society as a Steven Birnbaum Scholar and a Stohlman Scholar, and was elected to the Johns Hopkins Society of Scholars, the American Society of Clinical Investigation, and the Association of American Physicians.
|
|
| Michael V. Seiden, M.D., Ph.D. President Fox Chase Cancer Center |
Dr. Seiden is the President and Chief Executive Officer of the Fox Chase Cancer Center. As President, Dr. Seiden serves as the Principal Investigator for the NCI-sponsored Fox Chase Comprehensive Cancer Center grant. He also serves as the Principal Investigator for the NCI-funded Ovarian SPORE grant at Fox Chase and the University of Pennsylvania.
Prior to joining Fox Chase Cancer Center, Dr. Seiden served as the Chair of the Clinical Research Committee for the Gynecologic Cancer Program within the Dana Farber/Harvard Cancer Center and in 2004 he became the Director for Gynecologic Cancers Program for this NCI-supported program. His research interests at MGH included translational research in gynecologic malignancies with a focus on ovarian cancer. At MGH, he divided his time between patient care and clinical research focused on ovarian cancer, and bench-based molecular research looking to better define the molecular mechanisms of drug resistance.
Dr. Seiden received his BA in Chemistry at Oberlin College and his M.D. and Ph.D. at Washington University. His clinical training in internal medicine and medical oncology was completed at the Massachusetts General Hospital and the Dana Farber Cancer Institute.
|
|
| Gary Curhan, MD, ScD, Harvard Medical School |
Dr. Gary Curhan is an Associate Professor of Medicine at Harvard Medical School and Associate Professor of Epidemiology at Harvard School of Public Health. He is a practicing nephrologist at Brigham and Women’s Hospital and an active investigator with multiple NIH grants. Dr. Curhan’s research has focused on metabolic conditions (e.g. nephrolithiasis, gout), cardiovascular disease and cancer. He has authored over 150 articles and book chapters.
|
|
| George Teebor, MD, New York University School of Medicine |
Dr. George W. Teebor is Professor of Pathology and Environmental Medicine at the New York University School of Medicine where he has also served as Vice Dean for Research and Interim Chairperson of the Department of Pathology. He is a board certified pathologist and has been an NIH funded investigator for over 30 years including receipt of a MERIT Award. His research interest has been the etiology of cancer-initiating and/or promoting mutations and their prevention by the DNA repair machinery of the cell.
|
|